Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma

Journal of Clinical Oncology

Volumn 27, Issue 32, 2009, Pages 5452-5458

  O'Day, Steven ^a   Gonzalez, Rene ^a   Lawson, David ^a   Weber, Robert ^a   Hutchins, Laura ^a   Anderson, Clay ^a   Haddad, Jonathan ^a   Kong, Steven ^a   Williams, Anthony ^a   Jacobson, Eric ^a  

^a Saint Francis Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELESCLOMOL; PACLITAXEL; ANTINEOPLASTIC AGENT; HYDRAZINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAZARD RATIO; HEADACHE; HUMAN; HYPESTHESIA; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK REDUCTION; SOLID TUMOR; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSTIPATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; HYDRAZINES; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 73949153317     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.1579     Document Type: Article

References (38)

1. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 22:1118-1125, 2004
2. Middleton M, Hauschild A, Thomson D, et al: Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-alpha 2b, and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann Oncol 18:1691-1697, 2007
3. Patel PM, Suciu S, Mortier L, et al: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: Final results of the randomised Phase III study (EORTC 18032). Presented at the 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, September 12-16, 2008
4. Kirkwood J, Tarhini A, Panelli M, et al: Next generation of immunotherapy for melanoma. J Clin Oncol 26:3445-3455, 2008
5. Eggermont AM, Kirkwood JM: Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years? Eur J Cancer 40:1825-1836, 2004
6. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745, 2006
7. O'Day S, Boasberg P: Management of metastatic melanoma 2005. Surg Oncol Clin N Am 15: 419-437, 2006
8. Eggermont A: Reaching first base in the treatment of metastatic melanoma. J Clin Oncol 24: 4673-4674, 2006
9. Eton O, Talpaz M, Lee KH, et al: Phase II trial of recombinant human interleukin-2 and interferonalpha-2a: Implications for the treatment of patients with metastatic melanoma. Cancer 77:893-899, 1996
10. Sparano JA, Fisher RI, Sunderland M, et al: Randomized phase III trial of treatment with highdose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969-1977, 1993
11. Hamm C, Verma S, Petrella T, et al: Biochemotherapy for the treatment of metastatic malignant melanoma: A systematic review. Cancer Treat Rev 34:145-156, 2008
12. Ives N, Stowe R, Lorigan P, et al: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,261 patients. J Clin Oncol 25: 5426-5434, 2007
13. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759, 1998
14. Richards JM, Gale D, Mehta N, et al: Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17:651-657, 1999
15. Antoine EC, Benhammouda A, Bernard A, et al: Salpetriere Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 3:S16-S21, 1997 (suppl 1)
16. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002
17. Rowinsky E: Microtubule-targeting natural products, in Holland-Frei (ed): Cancer Medicine: Part IV. Therapeutic Modalities, Section 12. Chemotherapeutic Agents (ed 6). London, BC Decker, 2003, p 82
18. Ramanathan B, Jan K, Chen C, et al: Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65:8455-8460, 2005
19. Foley K, Bertin J, Chan K, et al: The oxidative stress inducer STA-4783 enhances the in vivo effi-cacy of multiple anti-cancer therapies in mouse tumor models. Presented at Program and Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. San Francisco, CA, October 22-26, 2007 (abstr A290)
20. Kirshner JR, He S, Balasubramanyam V, et al: Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7:2319-2327, 2008
21. Walker L, Schalch H, King DM, et al: Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res 15:453-459, 2005
22. Bedikian AY, Plager C, Papadopoulos N, et al: Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 14:63-66, 2004
23. Legha S, Ring S, Papadopoulos N, et al: A phase II trial of Taxol in metastatic melanoma. Cancer 65:2478-2481, 1990
24. Einzig A, Hochster H, Wiernik P, et al: A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs 9:59-64, 1991
25. Rao RD, Holtan SG, Ingle JN, et al: Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106:375-382, 2006
26. Zimpfer-Rechner C, Hofmann U, Figl R, et al: Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13:531-536, 2003
27. Wiernik P, Einzig A: Taxol in malignant melanoma. J Natl Cancer Inst Monogr 15:185-187, 1993
28. Hodi F, Soiffer R, Clark J, et al: Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25:283-286, 2002
29. Nathan F, Berd D, Sato T, et al: Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer 88:79-87, 2000
30. Retsas S, Mohith A, Mackenzie H: Taxol and vinorelbine: A new active combination for disseminated malignant melanoma. Anticancer Drugs 7:161-165, 1996
31. Wiernik P, Schwartz E, Einzig A, et al: Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 5:1232-1239, 1987
32. Berkenblit A, Eder JJ, Ryan D, et al: Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 13:584-590, 2007
33. Powderly J, Khan K, Urba W, et al: A 2-stage, randomized, blinded phase 2 study of sta-4783 in combination with paclitaxel in patients with advanced metastatic melanoma. J Clin Oncol 23:725s, 2005 (abstr 7561)
34. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92:205-216, 2000
35. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Can Chemother Rep 50:163-170, 1966
36. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Cox D: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
38. 2 from contingency tables, and the calculation of P. J R Stat Soc 85:87-94, 1922